Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Quantitative Analysis Of Cell-free DNA In The Plasma Of Gastric Cancer Patients.

Jong-lyul Park, H. Kim, B. Choi, Han-Chul Lee, Hay-Ran Jang, K. Song, Seung-Moo Noh, Seon-Young Kim, D. Han, Y. Kim
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
In the present study, an accurate and reproducible method for quantifying cell-free DNA (cfDNA) in human blood was established and tested for its ability to predict gastric cancer in patients. Using 'Alu81-qPCR' to amplify 81-bp Alu DNA sequences, we first estimated the amount of cfDNA in the serum or plasma of 130 patients with gastric cancer to identify which source of cfDNA is more suitable for the biomarker screening of these patients. The results of Alu81-qPCR revealed that the amount of cfDNA in the plasma was low compared with that in the serum, but was found at similar levels among the samples, indicating that the plasma may be a more suitable source of cfDNA for biomarker screening. For the 54 patients with gastric cancer and the 59 age-matched healthy controls, the mean levels of plasma cfDNA were 2.4-fold higher in the patient group compared with the control group, indicating that plasma cfDNA levels may be useful for predicting patients with gastric cancer. The results of our study suggest that Alu81-qPCR is a more reliable method than other techniques, such as the PicoGreen assay, for quantifying cfDNA in human blood, demonstrating the potential to complement current diagnostic procedures for the management of gastric cancer patients.
This paper references
10.1189/jlb.0704411
The effect of inflammation on the generation of plasma DNA from dead and dying cells in the peritoneum
N. Jiang (2005)
10.1196/annals.1318.013
Role of Cell‐Free Plasma DNA as a Diagnostic Marker for Prostate Cancer
D. Allen (2004)
10.1126/SCIENCE.306.5698.966
Inflammation and Cancer: The Link Grows Stronger
J. Marx (2004)
10.1038/sj.bjc.6601609
Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR
S. Gal (2004)
10.1373/CLINCHEM.2004.034553
Increased concentrations of cell-free plasma DNA after exhaustive exercise.
J. Atamaniuk (2004)
10.1046/j.1537-2995.2001.41020276.x
Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma
T. Lee (2001)
10.1373/CLINCHEM.2004.046219
Effects of preanalytical factors on the molecular size of cell-free DNA in blood.
K. Chan (2005)
10.1093/clinchem/48.3.421
Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation.
Y. Lui (2002)
10.1016/J.MRREV.2006.11.002
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.
E. Gormally (2007)
10.1200/JCO.2004.11.123
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
O. Gautschi (2004)
10.1373/CLINCHEM.2005.062893
Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool.
A. Pathak (2006)
10.1016/S0378-1119(00)00434-0
Densities, length proportions, and other distributional features of repetitive sequences in the human genome estimated from 430 megabases of genomic sequence.
Z. Gu (2000)
Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
J. Silva (2002)
10.1196/annals.1318.004
Quantification of Circulating DNA in the Plasma and Serum of Cancer Patients
B. Taback (2004)
10.1200/JCO.2003.02.006
Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer
G. Sozzi (2003)
Quantification of plasma DNA as a screening tool for lung cancer.
Guang-shun Xie (2004)
10.1373/clinchem.2008.104653
Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.
K. Chan (2008)
10.1097/00006676-199807000-00012
Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls.
M. B. Giacona (1998)
10.1093/JNCI/94.22.1697
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.
H. Chang (2002)
10.1196/annals.1368.040
Higher Amount of Free Circulating DNA in Serum than in Plasma Is Not Mainly Caused by Contaminated Extraneous DNA during Separation
N. Umetani (2006)
Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases.
Thijssen Ma (2002)
10.3322/caac.20107
Global cancer statistics
A. Jemal (2011)
10.1016/J.CANLET.2003.11.023
Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer.
K. Jung (2004)
10.3322/canjclin.55.2.74
Global Cancer Statistics, 2002
D. Parkin (2005)
10.1111/j.1464-410X.2008.07600.x
Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer
H. Schwarzenbach (2008)
10.1038/nm.1789
Circulating mutant DNA to assess tumor dynamics
F. Diehl (2008)
10.1373/CLINCHEM.2005.049320
Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR.
S. Holdenrieder (2005)
Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases.
M. A. Thijssen (2002)
Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations.
J. Silva (1999)
10.1002/CHIN.200505207
Extracellular Circulating Nucleic Acids in Human Plasma in Health and Disease
P. Laktionov (2005)
Cancer research. Inflammation and cancer: the link grows stronger.
J. Marx (2004)
Free DNA in the serum of cancer patients and the effect of therapy.
S. León (1977)
10.1016/0304-3835(95)03742-F
Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours.
G. Fournié (1995)
10.1373/CLINCHEM.2007.095992
DNA methylation biomarkers for blood-based colorectal cancer screening.
C. Lofton-Day (2008)



This paper is referenced by
10.3390/ijms19061610
Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy
G. Faria (2018)
Plasma cell-free DNA in diagnostic KRAS mutation testing
A. Isomursu (2015)
10.1186/s12885-016-2977-7
Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA
Wang-yang Pu (2016)
Diagnostic and prognostic value of circulating tumor- related DNA in cancer
Diego M. Marzese (2013)
10.1016/j.jmoldx.2017.06.004
Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing.
C. Alidousty (2017)
10.4103/aiao.aiao_32_18
Current status of cell-free DNA in head and neck cancer management
A. Singhal (2019)
10.3390/cancers11050641
Acute Tumor Transition Angle on Computed Tomography Predicts Chromosomal Instability Status of Primary Gastric Cancer: Radiogenomics Analysis from TCGA and Independent Validation
Y. Lai (2019)
10.3892/ol.2020.12264
Cell-free DNA as a liquid biopsy for early detection of gastric cancer
Zhengbin Huang (2021)
10.4172/2168-9652.1000E109
Circulating Cell-Free Nucleic Acids as Potential Biomarkers for Noninvasive Diagnosis of Diseases in the Future
S. Pehlivan (2012)
10.1007/s13277-016-5129-4
Noninvasive detection of gastric cancer
Qin-Si Wan (2016)
10.1007/s12253-020-00869-1
The Ratio of ssDNA to dsDNA in Circulating Cell-Free DNA Extract is a Stable Indicator for Diagnosis of Gastric Cancer
Xuewen Huang (2020)
10.1186/s40169-019-0229-6
Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer
H. Mirtavoos-mahyari (2019)
10.1016/J.MRREV.2019.05.002
Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review.
Klara Cervena (2019)
10.1159/000492917
Circulating Tumor DNA: A Step into the Future of Cancer Management
Joana Fernandes Marques (2019)
10.1038/s41598-020-72163-8
A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers
B. Koo (2020)
10.1038/bjc.2015.225
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
A. Szpechcinski (2015)
10.1016/j.bcp.2013.07.030
Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease.
I. Clark (2013)
Quantification of circulating plasma cell free DNA fragments in patients with oral cancer and precancer.
Ami P Desai (2018)
10.1016/j.ejca.2018.10.012
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
Z. Ye (2019)
10.3389/fonc.2020.00855
Early Detection of Non-Small Cell Lung Cancer by Using a 12-microRNA Panel and a Nomogram for Assistant Diagnosis
W. Wang (2020)
Measurement of circulating tumor DNA to guide management of patients with lymphoma.
D. Sriram (2019)
10.1007/978-3-319-48360-3_6
Gastric Cancer Biomarkers in Circulation
G. Dakubo (2017)
10.1515/cclm-2019-0896
Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction
J. Lee (2019)
10.1177/1756284819841896
Cell-free DNA testing: future applications in gastroenterology and hepatology
Inuk Zandvakili (2019)
Circulating DNA for detection of gastric cancer.
Q. Qi (2016)
Papel das biopsias líquidas no cancro esofágico, gástrico, pancreático e colo-retal
Tiago Costa (2017)
10.3748/wjg.v24.i21.2236
Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells
T. Li (2018)
Assessing Circulating Cell-free Tumour DNA as a Potential Biomarker for Early Detection and Chemoprevention of Colorectal Cancer
M. Myint (2017)
10.1200/JCO.2012.45.2011
Liquid biopsies: genotyping circulating tumor DNA.
L. Diaz (2014)
10.1186/s40880-016-0092-4
Cell-free circulating tumor DNA in cancer
Zhen Qin (2016)
10.1016/j.gpb.2016.12.004
Circulating Tumor DNA as Biomarkers for Cancer Detection
Xiao Han (2017)
10.1158/2159-8290.CD-17-0395
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
E. Pectasides (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar